RIGImmune Appoints Brett Haumann, MBBCh, MBA as Chief Executive Officer

NEWS PROVIDED BY
RIGImmune Inc. →
April 22, 2025, 08:00 ET

Brett Haumann, MBBCh, MBA has extensive respiratory product development experience

RIGImmune is advancing RIG-101 into a Phase 1/2 clinical study in asthma in 2H 2025

London & Farmington CT, April 22nd 2025: RIGImmune, Inc. today announced that Brett Haumann, MBBCh, MBA, has joined the company as chief executive officer and a director. Haumann succeeds Martin Driscoll, who transitions to non-executive director and remains chair of the RIGImmune board. Haumann assumes the leadership of RIGImmune as the company advances its lead product development candidate, intranasal RIG-101, into a Phase 1-2 clinical trial in asthma in the second half of this year. Haumann has consulted with RIGImmune for the past year and designed the initial clinical development plan for RIG-101.

“I am thrilled that we have been able to attract to RIGImmune such a seasoned and successful biopharmaceutical product developer and operational leader as Dr. Haumann,” said Martin Driscoll, chair of the RIGImmune board. “Brett is assuming the leadership of RIGImmune at an exciting point in our company’s young history as we advance our lead product, RIG-101, into the clinic later this year. Brett’s deep experience and successful record in respiratory product development coupled with his life sciences venture experience will substantially benefit RIGImmune as transition to a clinical-stage company.”

Haumann joins RIGImmune with 30 years’ industry experience and expertise including senior leadership roles in large pharma and biotech companies in the US and UK. Haumann has served as Chief Medical Officer in both private and publicly listed companies, including Circassia, Theravance Biopharma (where he oversaw the approval of inhaled Yupelri® for COPD) and ReViral (acquired by Pfizer in 2023). Previously Haumann spent 15 years at GlaxoSmithKline in a variety of executive roles in South Africa and the UK, spanning early drug discovery to clinical development and commercialization, rising to Vice President and Medicines Development Leader at GSK and leading the development of inhaled products for the treatment of asthma and COPD, including Relvar®, Breo® and Arnuity®.

Haumann also brings extensive life sciences venture investment experience from his ongoing role as an Operating Partner at SV Health Investors, a role he will continue to maintain going forward. Haumann has extensive board experience, having served as a non-executive director for several biopharmaceutical companies in the UK and US, including Autifony, Reacta and Aimmune (acquired by Nestle in 2020). Haumann currently serves a director for Aravax. Haumann received his medical degree (MBBCh) from the

University of Witwatersrand, South Africa, and his master's in business administration (MBA) with distinction from the Open University, UK.

"I'm honored to accept the role of CEO for RIGImmune and lead the company as we enter the clinic with our lead product development candidate," said Haumann. "I am impressed with the scientific progress that this talented and innovative team has made. I am passionate about the company's vision in developing RIG-101 as a potential first-in-class therapy for at-risk patients, notably asthmatics that commonly experience debilitating severe exacerbations due to an infectious respiratory disease during the cold season. I am committed to making a meaningful impact in building a strong and successful company as we advance RIG-101 into clinical development in in mid-2025."

About RIGImmune

RIGImmune is a private biopharmaceutical development company focused on developing novel therapies to address significant unmet clinical needs of patients with respiratory diseases. The company's lead product development candidate, RIG-101, is a novel proprietary intranasal therapy that could become a first-in-class innate immune modulator to prevent the consequences of common respiratory viral infections in at-risk patients, notably asthmatics that commonly suffer severe asthma exacerbations during the cold season each year. RIGImmune has also developed a proprietary non-LNP formulation platform called NEED™ (**N**ano-**E**mulsion **E**ffective **D**elivery) to optimally deliver RIG-101 and other payloads directly to the target tissues in the airways whilst avoiding the potential for adverse effects commonly associated with lipid nanoparticle (LNP) formulations.

RIGImmune has benefited by the support of several successful life sciences investors, including F-Prime Capital, Alembic, Inc., Connecticut Innovations, and the Gates Foundation.

About RIG-101

RIG-101 is a first-in-class intranasal RIG-I agonist that aims to restore the deficient innate immune response in asthmatics, preventing severe exacerbations caused by common respiratory viruses and not controlled by current asthma maintenance therapies. The intranasal route of delivery ensures that common respiratory viruses are rapidly cleared by the innate immune system before they can become sustained. Utilising RIGImmune's proprietary non-LNP NEED™ delivery platform, intranasal (IN) RIG-101 promises targeted drug delivery to the nose with minimal risk of systemic side effects or tissue inflammation, complementing existing asthma therapies and preventing loss of asthma control.

The company has designed an expedited clinical development program with the target to complete a clinically relevant proof-of-concept study in adult asthma by the end of 2026. RIG-101 also has potential utility in multiple at-risk populations, including paediatric asthma, COPD, those with suppressed immune systems such as cancer patients and other at-risk populations, positioning RIG-101 as a therapy with significant market potential. RIGImmune is on track to initiate the first human study of RIG0-101 in the second half of 2025.

About NEED™ (Nano-Emulsion Effective Delivery)

NEED™ is a proprietary non-LNP based formulation platform that avoids the inflammatory response associated with LNP-based systems. NEED™ exhibits shear-stable characteristics which are optimal for inhaled, intranasal and

systemic routes of administration. NEED™ enhances the uptake of a wide range of oligonucleotides into the target tissues, including the respiratory epithelium when given via the inhaled or intranasal route. NEED™ formulations are compatible with existing delivery devices.

Contact: info@rigimmune.com